TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 60
- 13F valueReported value at the end of Q2 2026
- $35.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TCRX, Q2 2026
No superinvestor reported holding TCRX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by TScan Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 23, 2025 (view filing)6:17 PM ET | Dec 19 | 4 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share ("Common Stock") | +80.1K | $0.8989 | +$72.0K | +1.0%7.94M after | |
| Dec 23, 2025 (view filing)6:17 PM ET | Dec 22-23 | 1 day | Nichols Weston and 1 other10% Owner | PPurchase | +81.7K | $0.8999 | +$73.6K | +1.0%8.02M after | 2 lots |
| May 21, 2025 (view filing)4:49 PM ET | May 19 | 2 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share ("Common Stock") | +1.39M | $1.20 | +$1.67M | +25.9%6.75M after | |
| May 21, 2025 (view filing)4:49 PM ET | May 20 | 1 day | Nichols Weston and 1 other10% Owner | PPurchase | +1.20M | $1.20 | +$1.44M | +17.8%7.95M after | |
| Dec 30, 2024 (view filing)4:15 PM ET | Dec 26 | 4 days | Nichols Weston and 1 other10% Owner | PPurchase | +7.50M | $4.00 | +$30.0M | –7.50M after | Derivative |
| Dec 16, 2024 (view filing)4:26 PM ET | Dec 12 | 4 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share ("Common Stock") | +31.8K | $3.01 | +$95.6K | +0.6%5.26M after | |
| Dec 16, 2024 (view filing)4:26 PM ET | Dec 13 | 3 days | Nichols Weston and 1 other10% Owner | PPurchase | +100.0K | $2.90 | +$290.1K | +1.9%5.36M after | |
| Nov 19, 2024 (view filing)4:26 PM ET | Nov 15 | 4 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share | +947 | $4.34 | +$4.11K | 0.0%5.23M after | |
| Sep 24, 2024 (view filing) | Sep 23 | 1 day | Klencke BarbaraDirector | PPurchaseVoting Common Stock | +5.00K | $5.29 | +$26.4K | +12.5%45.0K after | |
| Aug 27, 2024 (view filing) | Aug 23-26 | 4 days | Klencke BarbaraDirector | PPurchaseVoting Common Stock | +10.0K | $5.61 | +$56.1K | +33.3%40.0K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in TScan Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 8,019,148 | $7.86M | 0.91% | 00.0% | Unchanged |
| BVF Inc | 5,564,290 | $5.45M | 0.14% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 2,784,792 | $2.73M | 0.01% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 2,158,831 | $2.12M | 0.00% | +4,575+0.2% | Added |
| Two Sigma Investments, LP | 1,949,604 | $1.91M | 0.00% | +740,595+61.3% | Added |
| Renaissance Technologies LLC | 1,326,799 | $1.30M | 0.00% | −37,984−2.8% | Reduced |
| Acadian Asset Management LLC | 1,305,840 | $1.28M | 0.00% | +1,103,853+546.5% | Added |
| Deer Management Co. LLC | 1,245,504 | $1.22M | 0.15% | 00.0% | Unchanged |
| Millennium Management LLC | 1,163,611 | $1.14M | 0.00% | −296,674−20.3% | Reduced |
| Jacobs Levy Equity Management, Inc | 1,049,806 | $1.03M | 0.00% | +241,450+29.9% | Added |